Crossmark

Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors

Crossref DOI link: https://doi.org/10.1038/s41587-021-01024-0

Published Online: 2021-08-30

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abramson, Alex https://orcid.org/0000-0003-4876-9751
Frederiksen, Morten Revsgaard https://orcid.org/0000-0003-0000-4426
Vegge, Andreas

Jensen, Brian

Poulsen, Mette

Mouridsen, Brian

Jespersen, Mikkel Oliver

Kirk, Rikke Kaae

Windum, Jesper

Hubálek, František https://orcid.org/0000-0003-3983-7900
Water, Jorrit J.

Fels, Johannes https://orcid.org/0000-0002-6616-6746
Gunnarsson, Stefán B.

Bohr, Adam

Straarup, Ellen Marie

Ley, Mikkel Wennemoes Hvitfeld

Lu, Xiaoya

Wainer, Jacob

Collins, Joy

Tamang, Siddartha

Ishida, Keiko

Hayward, Alison

Herskind, Peter

Buckley, Stephen T. https://orcid.org/0000-0001-9804-7242
Roxhed, Niclas https://orcid.org/0000-0002-7147-6730
Langer, Robert https://orcid.org/0000-0003-4255-0492
Rahbek, Ulrik https://orcid.org/0000-0002-1255-0232
Traverso, Giovanni https://orcid.org/0000-0001-7851-4077
Funding

Funding for this research was provided by:

National Science Foundation

Novo Nordisk

Viking Olof Björk scholarship trust

U.S. Department of Health & Human Services | National Institutes of Health (EB-000244, EB-000244)

Massachusetts Institute of Technology

Viking Olof Björk scholarship trust
License Information

Text and Data Mining valid from 2021-08-30

Version of Record valid from 2021-08-30
More Information

Article History

Received: 8 April 2020

Accepted: 16 July 2021

First Online: 30 August 2021

Competing interests

: M.R.F., M.P., A.V., B.M., F.H., J.J.W., J.F., R.K.K., S.B.G., E.M.S., S.T.B., P.H., M.O.J., J. Windum, A.B., E.S. and U.R. are employees of Novo Nordisk. M.W.H.L. and B.J. are hired as consultants for Novo Nordisk. A.A., M.R.F., A.V., M.P., J.J.W., M.W.H.L., B.J., J. Windum, J. Wainer, X.L., N.R., U.R., G.T. and R.L. are co-inventors on patent applications describing oral biologic drug delivery. A.A., R.L. and G.T. report receiving consulting fees from Novo Nordisk. A.A. reports receiving consulting fees from Eli Lilly. Complete details of all relationships for profit and not for profit for G.T. can found at the following link: . For a list of entities with which R.L. is involved, compensated or uncompensated, see .

Document is current

Any future updates will be listed below